The field of gene editing recently got a major boost from Massachusetts-based Beam Therapeutics, and the company’s Durham ...

An R75W mutation in the gap junction β2 (GJB2) gene causes severe fragmentation of gap junction plaques, connecting adjacent ...

R75W mutation in the gap junction β2 (GJB2) gene causes severe fragmentation of gap junction plaques, connecting adjacent ...

Over 95% of babies now diagnosed with SMA are treated with Zolgensma gene therapy, per Daniel Grant, vice president for ...

Research on neuroprotective mechanisms aims to understand how the nervous system is protected from injury or degeneration. These studies commonly use animal ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...

Congenital hearing loss refers to impaired auditory function that occurs due to genetic causes. GJB2 is the gene responsible ...

The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...

Certain subsets of immune NK cells were altered in the blood of people with ALS, and could serve as therapeutic targets, a ...

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Chardan Capital in a research note issued to investors on Tuesday,Benzinga ...

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.

Base editing corrected a mutation that causes macular degeneration, highlighting the potential of gene therapy to treat ...